Evidence map›Paper›PMID 42234135›Full record

ArticleAnnals of hematology2026

Integrating genomic features for prognosis in Chinese patients with diffuse large B-cell lymphoma following R-CHOP therapy.

Shi Han, Linghui Zhou, Haiqiong Zheng, Yi Zhao, Zhen Cai, Jingsong He, Xiujin Ye, Wenjun Wu, Jie Sun, Weiyan Zheng and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Shi HanBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Linghui ZhouBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Haiqiong ZhengBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Yi ZhaoBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Zhen CaiBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Jingsong HeBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Xiujin YeBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Wenjun WuBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Jie SunBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Weiyan ZhengBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Guoqing WeiBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Li YuDepartment of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center of Shenzhen University, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518000, China.
Lixin WangDepartment of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center of Shenzhen University, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518000, China.
Ke GaoBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Juan YueBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Mingming ZhangBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China.
Yongxian HuBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China. 1313016@zju.edu.cn.
He HuangBone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310000, China. huanghe@zju.edu.cn.

Funding

National Natural Science Foundation of China 82341206, 82270234Sanming Project of Medicine in Shenzhen SZSM202111004the National Science Fund for Distinguished Young Scholars 82425002the Zhejiang Provincial Department of Science and Technology "Jianbing Lingyan+X" Research and Development Project Plan 2025C02075, 2024SSYS0023, 2024SSYS0025, 2024C03156
6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) exhibits 30-40% rates of relapse or refractory disease after R-CHOP. Identifying patients at risk for treatment failure is essential for planning subsequent therapeutic strategies, including stem cell mobilization or cellular therapy. To identify genomic predictors in Chinese patients, we performed targeted sequencing of tumor and matched oral DNA from 147 cases. Mutations in TP53 (hazard ratio (HR) = 2.78; P = 0.002), SRP72 (HR = 2.79; P = 0.010), MYC (HR = 1.97; P = 0.033), BCL2 (HR = 2.54; P = 0.021), and ASXL2 (HR = 2.20; P = 0.048) were significantly associated with poor PFS. A five-gene mutation risk score combined with baseline lactate dehydrogenase (LDH) and bone marrow tumor cell status improved PFS prediction over the International Prognostic Index (IPI). In addition, TP53 (HR = 4.45; P = 0.003), SRP72 (HR = 4.16; P = 0.014), and MYC (HR = 2.64; P = 0.047) mutations were strongly associated with increased risk of relapse. Integrating the three-gene mutation risk score with baseline LDH showed superior ability to predict relapse compared with the IPI. Combining mutation-derived scores with clinical factors enhanced prognostic discrimination, aiding early identification of patients for stem cell or cellular therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseMutationAdultAgedAntibodies, Monoclonal, Murine-DerivedChinaCyclophosphamideDoxorubicinEast Asian PeopleFemaleGenomicsHumansMaleMiddle AgedPrednisoneAntibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineDeoxyribonucleic acid detectionDiffuse large B-cell lymphomaGenomic biomarkersPrognosisRelapse risk

Identifiers

PMID42234135
PMCPMC13447478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.